Andrew T. Miller, Ph.D. is the Vice President of Immunology and Operations, and co-founder of Apros Therapeutics, a clinical stage biotech focused on tissue-targeted TLR7 agonists for cancer immunotherapy, infectious disease, and vaccine adjuvants. Andrew has a strong track record of leading small molecule and biologic drug discovery and development programs across a wide range of immunotherapeutic areas in both small biotech and big pharma settings from conception to early Phase 1 studies. Prior to co-founding Apros, Andrew served as a Senior Investigator at Novartis’ La Jolla campus (GNF) where he co-led numerous therapeutic programs in autoimmunity, cancer immunotherapy, and vaccines. Over the course of Andrew’s 20 year career in R&D, he has played an integral role on teams that have delivered 12 development candidates, 6 of which have entered the clinic. Andrew has authored >20 research articles and published patents. Andrew received his Ph.D. in Immunology and Virology from the University of Massachusetts Medical School, and a Bachelor’s degree in Finance and Operations Management from the University of Massachusetts at Amherst.